Preclinical Data Demonstrates Potential Of LX214 As Best-In-Class Topical Treatment For Chronic Inflammatory Diseases Of The Eye

Monday, August 4, 2008

Comments

Medical News Today

Lux Biosciences announced the presentation of preclinical data demonstrating the safety and pharmacokinetics of LX214 as a potential once-daily topical treatment for chronic inflammatory diseases of the eye.

Full Story

Which of the following is not consistent with a classic diagnosis of multiple evanescent white dot syndrome (MEWDS)?
1. Unilateral involvement
2. Foveal involvement of the white dots
3. Vitreous cell
4. Venous sheathing
5. Optic nerve edema
Check The Answer

CareCloud Charts For Ophthalmology
Get all of the tools you need to deliver... view product
Smartphone-Based Retinal Screening System
D-EYE, The Modern Day Digital ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Preclinical Data Demonstrates Potential Of LX214 As Best-In-Class Topical Treatment For Chronic Inflammatory Diseases Of The Eye

Comments

Quick Quiz

Which of the following is not consistent with a classic diagnosis of multiple evanescent white dot syndrome (MEWDS)?

AdGlare RMR Ad

Featured Products

CareCloud Charts For Ophthalmology

Smartphone-Based Retinal Screening System

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us